RIA
BMRN icon

Regal Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Regal Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$598K Buy
+10,592
New +$618K 0.03% 397
2015
Q4 		– Sell
-62
Closed -$6K – 339
2015
Q3 		$6K Buy
+62
New +$8.28K ﹤0.01% 775

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Regal Investment Advisors's BMRN Position: Q1 2026 in Review

Regal Investment Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 10,592 shares worth $598K. The stake represents 0.03% of the portfolio and ranks #397 among its holdings. This is a return to the name: Regal Investment Advisors previously reported a position in BMRN as recently as Q3 2015.

Regal Investment Advisors first reported a position in BMRN in Q3 2015 and has held it in 2 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Regal Investment Advisors held 10,592 shares of BioMarin Pharmaceuticals worth $598K as of Q1 2026.
  • BioMarin Pharmaceuticals was a new Regal Investment Advisors position in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.03% of Regal Investment Advisors's portfolio in Q1 2026, its #397 holding.
  • Regal Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2015 and has held it in 2 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Regal Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.